Trachoma is an infectious eye disease caused by the bacterium Chlamydia trachomatis. Trachoma primarily spreads through the parasitic bacteria. However, other factors such as poor sanitation and unhygienic water and food are also major causes for the spread of trachoma. In its early stages, trachoma leads to the development of conjunctivitis. In later stages, it can progress through repeated new infections leading to eye pain, scarring, and vision loss if left untreated. Trachoma is one of the leading causes of preventable blindness, with over 2.2 million people affected by this disease globally, of which 1.22 million people are affected with irreversible blindness. It is a contagious disease which spreads through direct or indirect contact with eye, eyelids, and secretions from nose and throat of an infected individual. According to WHO, around 232 million people living in trachoma endemic district poses high risk of developing trachoma. Antibiotics such as azithromycin and tetracycline are most commonly used the treatment of trachoma.
The global trachoma treatment market is projected to be driven by rise in incidence and prevalence of trachoma in under-developed and developing countries. Trachoma is most commonly observed in countries in Africa, Central and South America, Asia, Australia, and the Middle East. The development and adoption of ‘SAFE’ strategy by the World Health Organization for the global elimination of trachoma as public health problem is likely to be one of the leading factors driving the global trachoma treatment market during the forecast period. The SAFE strategy stands for Surgical care, Antibiotics for the clearance of Chlamydia trachomatis, Facial Cleanliness, and Environmental improvement. However, lack of awareness in these countries about the disease, low diagnosis rates, and poor health care facilities are projected to hamper the growth of the trachoma treatment market during the forecast period.
The global trachoma treatment market can be segmented based on drug class, route of administration, distribution channel, and region. In terms of drug class, the market can be categorized into tetracycline, macrolides, ophthalmic anti-infective, sulfonamides, and others. Macrolides are antibiotics developed from soil-borne bacteria Saccharopolyspora erythraea. The macrolides segment is projected to account for leading share of the global trachoma treatment market by 2025. The tetracycline segment is anticipated to account for second largest share of the global market by 2025. Based on route of administration, the global trachoma treatment market can be classified into oral and topical. In terms of distribution channel, the global market can be divided into hospital pharmacy, retail pharmacy, and e-commerce.
Geographically, the global trachoma treatment market can be segmented into four major regions: Asia Pacific, Latin America, Middle East & Africa, and Rest of the World. Middle East & Africa is projected to account for leading share of the global trachoma treatment market by 2025. Africa is the world’s most affected region by trachoma. According to the World Health Organization, in 2016, over 247,000 people in Africa were treated with surgical treatment for Trachiasis and around 83 million people were treated with antibiotic therapy. Asia Pacific is expected to account for the second leading share in the global market by 2025.
Key players operating in the global trachoma treatment market include Allergan plc, Pfizer, Inc., Apotex Corp., Sandoz, Inc. (Novartis AG), Teva Pharmaceutical Industries Ltd., Fresenius Kabi AG, Arbor Pharmaceuticals, Inc., AbbVie, Inc., and Merck & Co., Inc.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.